EXTRAPULMONARY NEUROENDOCRINE CARCINOMA (EP-NEC)
Clinical trials for EXTRAPULMONARY NEUROENDOCRINE CARCINOMA (EP-NEC) explained in plain language.
Never miss a new study
Get alerted when new EXTRAPULMONARY NEUROENDOCRINE CARCINOMA (EP-NEC) trials appear
Sign up with your email to follow new studies for EXTRAPULMONARY NEUROENDOCRINE CARCINOMA (EP-NEC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Radioactive 'Magic Bullet' tested against tough cancers
Disease control Recruiting nowThis study is testing a new radioactive drug called [212Pb]Pb-DOTAM-MAM279 in adults with advanced small cell lung cancer and other hard-to-treat solid tumors. The main goals are to find a safe and effective dose and to see if the treatment can shrink tumors. The drug is designed…
Matched conditions: EXTRAPULMONARY NEUROENDOCRINE CARCINOMA (EP-NEC)
Phase: PHASE1, PHASE2 • Sponsor: Molecular Partners AG • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
New hope for Tough-to-Treat cancers: first human trial of experimental drug begins
Disease control Recruiting nowThis early-stage study is testing a new drug called PT217 for people with advanced neuroendocrine cancers that have spread or come back after standard treatments. Researchers will first find the safest dose of PT217 given alone, then test it combined with chemotherapy. The goal i…
Matched conditions: EXTRAPULMONARY NEUROENDOCRINE CARCINOMA (EP-NEC)
Phase: PHASE1, PHASE2 • Sponsor: Phanes Therapeutics • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC